Highest-materiality recent filing
Net income attributable to shareholders of $24.1M ($1.94 basic EPS) vs. net loss of $5.1M a year ago.
vTv Therapeutics reports 2025 net loss of $27M; cash $88.9M; Phase 3 enrollment Q3 2026
Full-year 2025 net loss attributable to vTv of $27.0M ($3.20 basic EPS) vs $18.5M ($3.20 basic EPS) in 2024.
Second Amendment grants Newsoara global rights to PDE4 inhibitor HPP737 upon $20M upfront payment.
vTv Therapeutics Q3 net loss $8.7M; Phase 3 CATT1 data expected H2 2026
Net loss $8.7M ($1.08 per share) vs $4.8M loss ($0.88) in Q3 2024.
vTv Therapeutics raises up to $80M in private placement; initial close $65M on Sept 3
Raises up to $80M gross proceeds from private placement of 5,243,732 units at $15.265 per unit (or $15.255 with pre-funded warrant).
vTv Therapeutics Q2 net loss $6.0M; Phase 3 T1D trial randomized
Net loss attributable to vTv shareholders of $6.0M ($0.92/share) vs $5.2M ($0.81/share) in Q2 2024.
vTv Therapeutics Q1 2025 net loss $5.1M; cash $31.1M; cadisegliatin Phase 3 data expected 2H 2026
Net loss attributable to shareholders was $5.1M ($0.77 per share) vs $4.9M ($1.17 per share) in Q1 2024.
vTv Therapeutics FY2024 net loss $18.5M; clinical hold lifted, Phase 3 CATT1 to resume Q2 2025
Clinical hold on cadisegliatin program lifted March 14, 2025; Phase 3 CATT1 T1D trial to resume Q2 2025 with protocol amendment shortening to 6 months.
FDA lifts clinical hold on vTv Therapeutics' cadisegliatin Phase 3 diabetes trial
FDA lifted clinical hold effective March 14, 2025; CATT1 trial to resume after protocol amendment.
vTv Therapeutics Q3 net loss narrows to $4.8M; FDA clinical hold on cadisegliatin continues
Net loss of $4.8M ($0.88/share) vs $6.7M ($3.19) in Q3 2023; nine-month net loss $14.8M.
vTv Therapeutics receives termination notice for ppar-δ license from OnKure; effective Jan 2025
OnKure (formerly Reneo) notified vTv LLC intent to terminate the December 2017 License Agreement for vTv's ppar-δ agonist program IP.
vTv Therapeutics Q2 2024 net loss $5.2M; FDA places clinical hold on cadisegliatin T1D trial
Net loss $5.2M ($0.81/sh) vs $5.6M ($2.69/sh) in Q2 2023; cash $45.5M up from $9.4M year-end.
FDA places clinical hold on vTv Therapeutics' cadisegliatin Phase 3 trial for type 1 diabetes
FDA clinical hold based on unresolved chromatographic signal in cadisegliatin ADME study.
vTv Therapeutics Q1 net loss $4.9M; cash rises to $52.3M on $51M placement, Phase 3 on track
Cash $52.3M at March 31, up from $9.4M Dec 31, after $51M private placement from healthcare investors and JDRF T1D Fund.
vTv Therapeutics FY2023 net loss $20.3M; $51M PIPE funds Phase 3 cadisegliatin trial
Net loss attributable to shareholders $20.3M ($9.71/share) in FY2023 vs $19.2M ($9.98) in FY2022.
On May 19, 2025, vTv Therapeutics Inc. (the “Company”) announced that the Company has appointed Michael Tung as executive vice president and chief financial officer of the Company, effective as of May 19, 2025.
On April 11, 2025, the Board of Directors of vTv Therapeutics Inc. (the “Company”) appointed Barry K. Brown, age 64, as interim principal financial officer effective immediately.
On February 24, 2025, Steven Tuch, Executive Vice President and Chief Financial Officer of vTv Therapeutics Inc. (the "Company"), informed the Company of his intention to resign from his position effective March 21, 2025.
On March 12, 2024, Anne Phillips was elected as director of vTv Therapeutics, Inc. (the “Company”), effective and contingent on the filing of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, which occurred on March 13, 2024 (the “2023 Annual Report”).
John Fry and Howard Weiner resigned from their director roles effective upon the filing of the 2023 Annual Report.
John Fry and Howard Weiner resigned from their director roles effective upon the filing of the 2023 Annual Report.
Max materiality 0.80 · Median 0.55 · Most common event other_material